|
1
|
Alves RC, Alves D, Guz B, Matos C, Viana
M, Harriz M, et al: Advanced hepatocellular carcinoma. Review of
targeted molecular drugs. Ann Hepatol. 10:21–27. 2011.PubMed/NCBI
|
|
2
|
WalyRaphael S, Yangde Z and Yuxiang C:
Hepatocellular carcinoma: focus on different aspects of management.
ISRN Oncol. 2012:4216732012.PubMed/NCBI
|
|
3
|
Johnson PJ, Qin S, Park JW, Poon RT, Raoul
JL, Philip PA, et al: Brivanib versus sorafenib as first-line
therapy in patients with unresectable, advanced hepatocellular
carcinoma: results from the randomized phase III BRISK-FL study. J
Clin Oncol. 31:3517–3524. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Blackadar CB: Systematic review of
hepatocellular carcinoma mortality rates among hepatitis B
virus-infected renal transplant recipients, with supplemental
analyses of liver failure and all-cause mortality. Int J Infect
Dis. 17:e24–e36. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yin PH, Liu X, Qiu YY, Cai JF, Qin JM, Zhu
HR and Li Q: Anti-tumor activity and apoptosis-regulation
mechanisms of bufalin in various cancers: new hope for cancer
patients. Asian Pac J Cancer Prev. 13:5339–5343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamaguchi M: Suppressive role of
regucalcin in liver cell proliferation: involvement in
carcinogenesis. Cell Prolif. 46:243–253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fabregat I: Dysregulation of apoptosis in
hepatocellular carcinoma cells. World J Gastroenterol. 15:513–520.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ehrhardt C and Ludwig S: A new player in a
deadly game: influenza viruses and the PI3K/Akt signalling pathway.
Cell Microbiol. 11:863–871. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang CZ, Wang XD, Wang HW, Cai Y and Chao
LQ: Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT,
and PI3K expression. J BUON. 20:218–222. 2015.PubMed/NCBI
|
|
10
|
Yan CM, Chai EQ, Cai HY, Miao GY and Ma W:
Oleuropein induces apoptosis via activation of caspases and
suppression of phosphatidylinositol 3-kinase/protein kinase B
pathway in HepG2 human hepatoma cell line. Mol Med Rep.
11:4617–4624. 2015.PubMed/NCBI
|
|
11
|
Beliaeva MI: Modern views of causes of
microvascular complications development and progression in type 2
diabetes mellitus and peculiarities of their treatment. Vestn
Oftalmol. 129:70–75. 2013.(In Russian). PubMed/NCBI
|
|
12
|
Baffy G, Brunt EM and Caldwell SH:
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an
emerging menace. J Hepatol. 56:1384–1391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bertz J, Zang C, Liu H, Wächter M,
Possinger K, Koeffler HP and Elstner E: Compound 48, a novel dual
PPAR alpha/gamma ligand, inhibits the growth of human CML cell
lines and enhances the anticancer-effects of imatinib. Leuk Res.
33:686–692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han S, Ritzenthaler JD, Zheng Y and Roman
J: PPARbeta/delta agonist stimulates human lung carcinoma cell
growth through inhibition of PTEN expression: the involvement of
PI3K and NF-kappaB signals. Am J Physiol Lung Cell Mol Physiol.
294:L1238–L1249. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Geng J, Li X, Lang X, Qiao C, Hu M, Yang
J, et al: Combination of cetuximab and rapamycin enhances the
therapeutic efficacy in hepatocellular carcinoma. Technol Cancer
Res Treat. 13:377–385. 2014.PubMed/NCBI
|
|
16
|
Yang P, Zhang Y, Pang J, Zhang S, Yu Q, He
L, Wagner KU, Zhou Z and Wang CY: Loss of Jak2 impairs endothelial
function by attenuating Raf-1/MEK1/Sp-1 signaling along with
altered eNOS activities. Am J Pathol. 183:617–625. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mao F, Zhang L, Cai MH, Guo H and Yuan HH:
Leonurine hydrochloride induces apoptosis of H292 lung cancer cell
by a mitochondria-dependent pathway. Pharm Biol. 9:1–7. 2015.(Epub
ahead of print).
|
|
18
|
Yaidikar L and Thakur S: Punicalagin
attenuated cerebral ischemia-reperfusion insult via inhibition of
proinflammatory cytokines, up-regulation of Bcl-2, down-regulation
of Bax, and caspase-3. Mol Cell Biochem. 402:141–148. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu JJ, Hu T, Wu XY, Wang CZ, Xu Y, Zhang
Y, et al: Peroxisome proliferator-activated receptor-gamma agonist
rosiglitazone-induced apoptosis in leukemia k562 cells and its
mechanisms of action. Int J Toxicol. 28:123–131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu LH, Cheng NS, Xiong XZ and Wei DP:
Effect of PPAR-gamma ligand RGZ on inhibiting the cell
proliferation of cholangiocarcinoma. Sichuan Da Xue Xue Bao Yi Xue
Ban. 38:295–297. 2007.(In Chinese). PubMed/NCBI
|
|
21
|
Ciarcia R, Damiano S, Montagnaro S,
Pagnini U, Ruocco A, Caparrotti G, et al: Combined effects of PI3K
and SRC kinase inhibitors with imatinib on intracellular calcium
levels, autophagy and apoptosis in CML-PBL cells. Cell Cycle.
12:2839–2848. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sawayama H, Ishimoto T, Watanabe M,
Yoshida N, Sugihara H, Kurashige J, et al: Small molecule agonists
of PPAR-γ exert therapeutic effects in esophageal cancer. Cancer
Res. 74:575–585. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kulkarni S, Sitaru C, Jakus Z, Anderson
KE, Damoulakis G, Davidson K, et al: PI3Kβ plays a critical role in
neutrophil activation by immune complexes. Sci Signal.
4:ra232011.PubMed/NCBI
|
|
24
|
Koyasu S: The role of PI3K in immune
cells. Nat Immunol. 4:313–319. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen J: Roles of the PI3K/Akt pathway in
Epstein-Barr virus-induced cancers and therapeutic implications.
World J Virol. 1:154–161. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang YJ, Zhang AQ, Zhao XX, Tian ZL and
Yao L: Nicorandil protects against ischaemia-reperfusion injury in
newborn rat kidney. Pharmacology. 92:245–256. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fujita M, Yagami T, Fujio M, Tohji C,
Takase K, Yamamoto Y, et al: Cytotoxicity of troglitazone through
PPARγ-independent pathway and p38 MAPK pathway in renal cell
carcinoma. Cancer Lett. 312:219–227. 2011. View Article : Google Scholar : PubMed/NCBI
|
